Table 6 Cost-benefit analyses of vaccination programs in the general population

Country

Israel

Barbados

Caribbean

Year

1984

1998

2000

WB income group

High

High

Upper-middle

Comparators

1. Vaccinate all 1 - 12-yr-olds

1. Rubella elimination initiative

1. Initiative to interrupt rubella transmission

2. Vaccinate pubertal girls

2. None

2. None

3. Vaccinate adult females

Perspective

Societal*

Payer*

Payer*

Cost components measured

Laboratory tests; abortions; primary care; institutional care; lost work days;

NR

NR

Method of cost estimation

Micro-costing

NR

NR

Method of benefits estimation

Averted costs

NR

NR

Time period for costs and benefits

10 years

15 years

20 years

Discounting (Rate)

Yes (10%)

NR

NR

Results—Benefit-cost ratio

1. 1

1. 4.7

1. 13.3

2. 2

2. –

2. –

3. Negative

Stated conclusion

Vaccination of children and pubertal girls is preferable

The rubella elimination program using MMR was cost-beneficial

The rubella elimination program using MMR was cost-beneficial

Sponsor

NR

NR

NR